What is the 13F Pro Quality Score for ADIL?

13F Pro ranks ADIAL PHARMACEUTICALS, INC. (ADIL) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ADIL's current score at https://13fpro.ai/research/ADIL (free sign-up required for the full ranking).

Where does 13F Pro source ADIL data?

All ADIAL PHARMACEUTICALS, INC. fundamentals and ownership data come directly from SEC EDGAR. ADIAL PHARMACEUTICALS, INC. files with the SEC under CIK 1513525. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ADIL in?

ADIAL PHARMACEUTICALS, INC. (ADIL) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ADIL research updated on 13F Pro?

ADIL's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

ADIAL PHARMACEUTICALS, INC.(ADIL)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1513525 ADIL stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Below size threshold

Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ADIL Stock Analysis & AI Quality Score

AI stock analysis and institutional research for ADIAL PHARMACEUTICALS, INC. (ADIL), a Healthcare sector company. ADIL is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), ADIAL PHARMACEUTICALS, INC. reports net income of $-2.0M, free cash flow of $-1.6M. Top institutional holders of ADIL by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD FIDUCIARY CO, Manchester Capital Management, based on the most recent SEC filings. ADIL trades on the Nasdaq exchange and files with the SEC under CIK 1513525. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADIL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ADIAL PHARMACEUTICALS, INC. directly from SEC EDGAR.

Net Income

Q1 2026

$-2.0M

Free Cash Flow

Q1 2026

$-1.6M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+39.6% YoY

$-8.0MFY 2025

FY21 $-19.4MFY23 $-5.1MFY24 $-13.2MFY25 $-8.0M

Operating Income

+5.9% YoY

$-7.8MFY 2025

FY21 $-19.3MFY23 $-6.9MFY24 $-8.3MFY25 $-7.8M

EPS (Diluted)

+82.5% YoY

$-11.93FY 2025

FY21 $-1.04FY23 $-3.60FY24 $-68.01FY25 $-11.93

Total Assets

+32.3% YoY

$6.7MFY 2025

FY21 $7.5MFY23 $4.7MFY24 $5.0MFY25 $6.7M

Op. Cash Flow

+6.2% YoY

$-6.5MFY 2025

FY21 $-11.9MFY23 $-6.8MFY24 $-6.9MFY25 $-6.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2020	FY 2019
Net Income	$-8.0M +39.6%	$-13.2M -157.6%	$-5.1M +73.6%	$-19.4M -78.3%	$-10.9M -26.8%	$-8.6M
Operating Income	$-7.8M +5.9%	$-8.3M -20.3%	$-6.9M +64.3%	$-19.3M -76.5%	$-10.9M -32.5%	$-8.2M
EPS (Diluted)	$-11.93 +82.5%	$-68.01 -1789.2%	$-3.60 -246.2%	$-1.04	—	—
Total Assets	$6.7M +32.3%	$5.0M +6.5%	$4.7M -36.6%	$7.5M +36.1%	$5.5M -28.5%	$7.7M
Operating Cash Flow	$-6.5M +6.2%	$-6.9M -1.7%	$-6.8M +43.0%	$-11.9M -56.5%	$-7.6M -20.4%	$-6.3M

AI Insight: ADIL Financial Trends

ADIL generates zero revenue across all eight quarters, burning ~$2M per quarter with equity now at $4M — runway is critically thin.

• Revenue is absent in every quarter from Q2 2024 through Q1 2026, confirming pre-commercial stage status.

• Net loss has held steady at -$2M per quarter for eight consecutive quarters, indicating a consistent but unrelenting cash burn.

• Equity peaked at $6M in Q3 2024 and Q2 2025 but has since declined to $4M in Q1 2026, suggesting capital raises are barely offsetting losses.

⚠ Equity of $4M against ~$2M quarterly cash burn implies fewer than two quarters of runway without additional financing.

⚠ Equity volatility (swinging $2M–$6M) suggests episodic equity raises — watch for dilutive issuances.

AI Insight: ADIL Ratio Trends

Data is too sparse to identify reliable trends — only ROE is available across a handful of quarters, all deeply negative.

• ROE was -149.0% in Q3 2024, improved slightly to -140.1% in Q2 2025, then deteriorated to -159.3% in Q3 2025.

• ROE of -151.3% in Q4 2025 remains deeply negative; all other key ratios — OpMargin, NPM, ROA, ROIC, D/E — are unavailable.

⚠ Persistent deeply negative ROE across every reported quarter signals ongoing net losses relative to equity with no visible improvement trend.

⚠ Near-total absence of ratio data limits visibility into leverage, cash generation, and operational efficiency — a transparency risk.

Get alerted when ADIL's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for ADIAL PHARMACEUTICALS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ADIL

GEODE CAPITAL MANAGEMENT, LLC
$43.4K24,249 sh
VANGUARD FIDUCIARY TRUST CO
$10.5K5,879 sh
Manchester Capital Management LLC
$3.4K1,923 sh
Tower Research Capital LLC (TRC)
$2.4K1,356 sh
BlackRock, Inc.
$2.0K1,110 sh
UBS Group AG
$970.00542 sh
VANGUARD CAPITAL MANAGEMENT LLC
$646.00361 sh
MORGAN STANLEY
$90.0050 sh
SBI Securities Co., Ltd.
$84.0047 sh
Caitong International Asset Management Co., Ltd
$27.0015 sh

Fund	Value	Shares
GEODE CAPITAL MANAGEMENT, LLC	$43.4K	24,249
VANGUARD FIDUCIARY TRUST CO	$10.5K	5,879
Manchester Capital Management LLC	$3.4K	1,923
Tower Research Capital LLC (TRC)	$2.4K	1,356
BlackRock, Inc.	$2.0K	1,110
UBS Group AG	$970.00	542
VANGUARD CAPITAL MANAGEMENT LLC	$646.00	361
MORGAN STANLEY	$90.00	50
SBI Securities Co., Ltd.	$84.00	47
Caitong International Asset Management Co., Ltd	$27.00	15

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ADIL on your watchlist

Track score changes the day ADIAL PHARMACEUTICALS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ADIL a good stock to buy?

13F Pro's AI-powered analysis of ADIAL PHARMACEUTICALS, INC. (ADIL) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ADIL are available on the ADIL stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ADIL?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ADIL. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ADIAL PHARMACEUTICALS, INC.'s investment landscape.